US · ORGO
Organogenesis Holdings Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Canton, MA 02021
- Website
- organogenesis.com
Price · as of 2025-12-31
$2.57
Market cap 407.39M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $52.28 | +1,934.24% |
| Intrinsic Value(DCF) | $191.62 | +7,356.03% |
| Graham-Dodd Method(GD) | $3.04 | +18.29% |
| Graham Formula(GF) | $10.95 | +326.15% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | $9.91 | ||||
| 2017 | $9.90 | ||||
| 2018 | $7.38 | $0.00 | $0.00 | ||
| 2019 | $3.51 | $32.12 | $0.00 | $0.00 | $0.00 |
| 2020 | $17.72 | $47.62 | $0.50 | $1.85 | $5.83 |
| 2021 | $7.62 | $47.71 | $239.82 | $5.33 | $32.79 |
| 2022 | $2.28 | $32.57 | $0.00 | $2.42 | $0.56 |
| 2023 | $3.11 | $29.26 | $0.00 | $2.09 | $0.16 |
| 2024 | $5.16 | $31.43 | $0.00 | $2.54 | $0.12 |
| 2025 | $3.00 | $52.28 | $0.67 | $3.04 | $10.95 |
AI valuation
Our deep-learning model estimates Organogenesis Holdings Inc.'s (ORGO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $52.28
- Current price
- $2.57
- AI upside
- +1,934.24%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$191.62
+7,356.03% upside
Graham-Dodd
$3.04
+18.29% upside
Graham Formula
$10.95
+326.15% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ORGO | Organogenesis Holdings In… | $2.57 | 407.39M | +1,934% | +7,356% | +18% | +326% | 10.27 | 1.27 | 0.67 | 5.43 | — | 1.45 | 73.57% | 7.92% | 10.09% | 10.81% | 15.37% | 6.75% | 0.27 | 19.59 | 3.62 | 3.11 | -0.17 | -160000.00% | 1704.00% | -68573.00% | -6.43% | -0.10 | -8.41% | 2.99% | 30.70% | 2.99% | 8.25 | -15.07 | 0.65 | 3.09 |
| ANGO | AngioDynamics, Inc. | $11.44 | 471.53M | +233% | -70% | -97% | — | -10.26 | 1.91 | 1.19 | 168.52 | — | 3.06 | 53.92% | -13.66% | -11.62% | -17.50% | -30.54% | -11.37% | 0.00 | — | 2.21 | 1.30 | -32.16 | -8192.00% | -376.00% | -5699.00% | -4.18% | -0.13 | -11.17% | 0.00% | 0.00% | 0.48% | -7.33 | -20.07 | 1.00 | 0.98 |
| BCYC | Bicycle Therapeutics plc | $5.73 | 397.02M | +373% | +110% | — | — | -3.52 | 0.75 | 16.88 | 1.67 | — | 0.75 | -390.34% | -594.96% | -479.18% | -29.04% | 217.72% | -21.78% | 0.01 | -121.31 | 13.81 | 13.61 | 5.28 | -4291.00% | 3076.00% | 16112.00% | -27.87% | -2.45 | 177.02% | 0.00% | 0.00% | 65.25% | 1.31 | 1.65 | -7.78 | 1.58 |
| CMPX | Compass Therapeutics, Inc… | $5.65 | 781.32M | — | — | — | — | -7.47 | 2.95 | 433.91 | -4.53 | -82.17 | 2.95 | 100.00% | -6661.76% | -5808.82% | -36.07% | -3833.78% | -33.22% | 0.05 | — | 14.96 | 14.28 | 0.67 | 909.00% | — | 1046.00% | -12.17% | -5.05 | -3039.88% | 0.00% | 0.00% | 3.89% | -4.39 | -5.54 | 292.63 | 10.68 |
| EBS | Emergent BioSolutions Inc… | $8.15 | 434.81M | +481% | -56% | +80% | — | 9.14 | 0.92 | 0.65 | 3.56 | — | 5.59 | 48.62% | 13.47% | 7.08% | 10.46% | 6.53% | 3.88% | 1.09 | 1.69 | 5.01 | 2.19 | 1.54 | -12583.00% | -2881.00% | 33799.00% | 32.60% | 1.29 | 16.09% | 0.00% | 0.00% | 48.82% | 8.47 | 5.41 | 1.14 | 1.49 |
| EOLS | Evolus, Inc. | $4.30 | 278.73M | +754% | +521% | — | — | -16.70 | 152.52 | 3.16 | -35.41 | — | -13.07 | 68.46% | -12.92% | -18.94% | 664.86% | -75.16% | -23.92% | 23.54 | -1.84 | 2.40 | 2.14 | -1.72 | -2500.00% | 3176.00% | -4536.00% | -2.31% | -0.29 | -42.53% | 0.00% | 0.00% | 2.46% | -25.72 | -45.46 | 3.32 | -0.33 |
| ESPR | Esperion Therapeutics, In… | $3.35 | 661.73M | +1,302% | +27,124% | — | — | -6.11 | -0.81 | 0.95 | 100.78 | — | -0.81 | 79.36% | 16.37% | -15.57% | 12.27% | 177.11% | -18.83% | -1.52 | 0.92 | 1.37 | 0.91 | 58.98 | -8621.00% | 18566.00% | -8231.00% | -7.58% | -0.10 | -78.04% | 0.00% | 0.00% | 3.87% | 14.02 | -31.82 | 2.30 | -4.45 |
| MNPR | Monopar Therapeutics Inc. | $54.81 | 366.24M | — | — | — | — | -20.88 | 5.91 | — | -16.41 | -15.53 | 5.91 | 0.00% | — | — | -51.42% | 471.62% | -46.09% | 0.00 | — | 11.47 | 11.46 | 2.83 | 13448.00% | — | -1850.00% | -1.97% | -1.22 | 186.88% | 0.00% | 0.00% | 11.85% | -16.41 | -41.42 | — | 35.62 |
| SIGA | SIGA Technologies, Inc. | $6.47 | 463.33M | +352% | -48% | — | -5% | 6.20 | 1.70 | 2.65 | 3.01 | — | 1.71 | 77.44% | 50.45% | 42.69% | 28.70% | 100.67% | 23.75% | 0.00 | — | 9.12 | 6.97 | -2.20 | -1263.00% | -86.00% | -4860.00% | 13.27% | 1.92 | 90.03% | 11.62% | 72.10% | 13.06% | 3.03 | 4.36 | 1.53 | 10.11 |
| SNDL | SNDL Inc. | $1.54 | 396.55M | +1,401% | +62% | -9% | — | -5.99 | 0.51 | 0.63 | -11.63 | — | 0.61 | 26.11% | -11.28% | -10.30% | -8.20% | -8.54% | -6.82% | 0.13 | -13.49 | 5.10 | 3.06 | 1.60 | -4162.00% | 126.00% | -27858.00% | 7.62% | 0.61 | 3.96% | 0.00% | 0.00% | 8.92% | -4.62 | 10.92 | 0.52 | 0.99 |
| VREX | Varex Imaging Corporation | $13.17 | 552.08M | +77% | -64% | — | — | -6.94 | 1.03 | 0.57 | 209.03 | -15.31 | 1.86 | 34.39% | -3.29% | -8.32% | -13.87% | -3.65% | -6.01% | 0.85 | -0.78 | 3.43 | 1.67 | 73.40 | 4530.00% | 414.00% | -784.00% | 3.88% | 0.22 | 2.47% | 0.00% | 0.00% | 9.24% | -26.32 | 38.91 | 0.87 | 1.63 |
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
- CEO
- Gary S. Gillheeney
- Employees
- 869
- Beta
- 1.40
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($191.62 ÷ $2.57) − 1 = +7,356.03% (DCF, example).